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Murine double minute-2 protein (Mdm2) is a multifaceted phos-
phorylated protein that plays a role in regulating numerous
proteins including the tumor suppressor protein p53. Mdm2 binds
to and is involved in conjugating either ubiquitin or Nedd8 (Neural
precursor cell expressed, developmentally down-regulated 8) to
p53. Although regulation of the E3 ubiquitin activity of Mdm2 has
been investigated, regulation of the neddylating activity of Mdm2
remains to be defined. Here we show that activated c-Src kinase
phosphorylates Y281 and Y302 of Mdm2, resulting in an increase in
Mdm2 stability and its association with Ubc12, the E2 enzyme of the
neddylating complex. Mdm2-dependent Nedd8 conjugation of p53
results in transcriptionally inactive p53, a process that is reversed
with a small molecule inhibitor to either Src or Ubc12. Thus, our
studies reveal howMdm2 may neutralize and elevate p53 in actively
proliferating cells and also provides a rationale for using therapies
that target the Nedd8 pathway in wild-type p53 tumors.
Mdm2 | Src | Nedd8
Although c-Src is rarely mutated in human cancers, aberrantactivation of this nonreceptor tyrosine kinase is correlated
with clinical progression of cancer in numerous tumors derived
from different organ systems. Specifically, c-Src is involved in
a multitude of tumor progression properties including survival,
angiogenesis, migration, and adhesion (1). However, c-Src alone
is not a strong transforming agent, which is not surprising con-
sidering that transformation is a multifaceted process requiring
activation of oncogenes and hyperactivation of signaling path-
ways (2, 3). One of the downstream effectors of c-Src is the
survival factor Akt. Akt has been shown to phosphorylate many
substrates to promote cell survival, including the murine double
minute-2 protein (Mdm2) (4, 5). Mdm2 undergoes nuclear
translocation in response to Akt phosphorylation at serine 166
and 186 (5). Once in the nucleus, Mdm2 binds to tumor sup-
pressor p53 and inhibits its activity. However, in response to
genotoxic stress, Mdm2 is phosphorylated by numerous serine,
threonine, and tyrosine kinases that result in increased abun-
dance and activity of p53 (6-10). Conversely, under growth
conditions, p53 is elevated, yet largely inactive, suggesting there
are distinct pathways involved in regulating p53.
One intriguing mechanism that leads to the inactivation of
p53 is Mdm2-mediated conjugation of Nedd8 (Neural precursor
cell expressed, developmentally down-regulated 8) (11). In a similar
fashion to the ubiquitin system, neddylation involves the activation
and transfer of Nedd8 from E1 (APP-BP1 in human) to E2
(Ubc12) and E3 really interesting new gene (RING) ligases. In
addition, there are de-neddylating enzymes, such as constitutive
photomorphogenic (COP9), COP9 signalisome (CSN), and Nedd8
specific protease1 (NEDP1), that act on p53 in response to geno-
toxic stress (12–14). Physiologically, the Nedd8 pathway is crucial
for viability in mice, Caenorhabditis elegans, and Schizosaccharo-
myces pombe (15), and pathologically, Nedd8-conjugated proteins
have been shown to be elevated in certain types of cancer (16).
Thus, dependent on the cellular signaling, the Mdm2–p53
interplay may be differentially regulated. Here we examine the
possibility that Mdm2 activity is altered and becomes a neddy-
lating enzyme in response to growth factors. We show a novel
Mdm2/c-Src interaction that results in the phosphorylation of
Mdm2 at Y281 and Y302. Further analysis revealed that under
growth conditions, neither Mdm2 nor p53 is able to be ubiq-
uitinated. The neddylation activity of Src-phosphorylated Mdm2,
in contrast, was evident, as both Mdm2 and p53 were conjugated
with Nedd8. This switch of Mdm2 activity results in stagnant but
elevated levels of p53. Src-mediated activation of the neddylating
function of Mdm2 provides a mechanism for inactive but stable p53.
Results
Mdm2 Interacts with the Src Homology 3 Domain of c-Src in Vitro and
in Vivo. Mdm2 binds to and is a substrate for the nonreceptor
kinase c-Abl under genotoxic stress conditions (7). c-Abl con-
tains a Src homology 3 (SH3) domain, which binds to partner
proteins also containing an SH3 binding domain (PxxP). Human
Mdm2 contains two SH3 binding domains, so we tested whether
Mdm2 could bind to other SH3 domain-containing tyrosine
kinases by screening an SH3 domain array from Panomics. Using
recombinant human Mdm2, we found that Mdm2 binds to c-Abl,
Abl2, c-Src, and Hck (Table S1). Because of the prominent role of
c-Src in oncogenesis, we pursued the interaction between c-Src and
Mdm2 further. A series of Mdm2 truncations were generated,
and a GST-pull-down assay showed that they all bound to the SH3-
Src domain, but not to GST alone (Fig. S1A), revealing that the
portion of Mdm2 needed for the Src interaction is between resi-
dues 102 and 268, where the SH3-1 domain was located. Mutation
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(prolines-alanines) of the amino terminal SH3 binding domain
(mtSH3-1) of Mdm2 did not bind GST-SH3Src in a nickel pull-
down assay. The carboxy terminal SH3 domain mutant (mtSH3-2)
and wild-type Mdm2 maintained the ability to bind GST-SH3Src
(Fig. 1A). To further validate this interaction in vivo, an immu-
noprecipitation of endogenous c-Src or endogenous Mdm2
(MCF7, U87, or 293T cells) revealed that Mdm2 and c-Src form
a complex (Fig. 1B). Furthermore, c-Src and Mdm2 were pre-
dominantly found in the nuclear fraction (Fig. 1C). Thus, in vitro
and in vivo data provide evidence for an Mdm2/c-Src complex.
c-Src Phosphorylates Mdm2 at Y281 and Y302. Mdm2 is a highly
phosphorylated protein, and yet only two tyrosine kinases (Abl
and EGFR) have been identified as phosphorylating Mdm2 (7,
17, 18). There are 14 conserved tyrosines in Mdm2 (human and
mouse), three of which are already identified as c-Abl phos-
phorylation sites (Fig. 2A). To determine whether c-Src could
phosphorylate Mdm2, an in vitro phosphorylation reaction was
performed using 32P γ-labeled ATP. As expected, Mdm2 was
phosphorylated by c-Src and c-Abl (positive control) (Fig. 2B).
Using the phospho-tyrosine antibody 4G10, we show that Mdm2
(recombinant and transiently expressed) was tyrosine phosphory-
lated by Src (Fig. 2 C and D). Endogenous analysis of Mdm2
showed that treatment of MCF7 cells for 16 h with PP1 (a se-
lective Src inhibitor) resulted in a loss of tyrosine phosphorylation
of Mdm2 (Fig. 2E). Thus, our in vitro and in vivo data show that
Mdm2 is a substrate for Src.
To identify the c-Src phosphorylation sites, we performed
mass spectrometry on Mdm2 isolated from actively proliferating
T47D and MDA 231 cells. The data show, with high confidence,
that b and y ions were recovered for peptides that contained
Y302 of Mdm2 (Fig. S1B). We also noted that the peptide
containing Y281 was recovered but was in low abundance. The
difficulty in recovering this peptide was most likely a result of
issues involving enzymatic digestion and fragment sizes amena-
ble for analysis. With high confidence, peptides that contained
Y276, Y394, and Y405 (Abl phosphorylation sites) were re-
covered, but these sites were not phosphorylated. To verify the
mass spectrometry data, we performed in vitro phosphorylation
reactions and found that the double mutant (Y281-302F) was
also not phosphorylated (Fig. 2F). These data show, through
diverse approaches, that Y281 and Y302 are bona fide phos-
phorylation sites for Src.
c-Src Elevates Mdm2 Protein Levels. We examined the possibility
that Src phosphorylation would decrease the levels of Mdm2, as
we have previously shown that Abl phosphorylation induces
destabilization (6). Contrary to Abl phosphorylation of Mdm2,
we unexpectedly observed that Mdm2 protein levels increased
concomitantly as constitutively active (CA)-Src levels increased
(Fig. 3A), and as Fig. 3B shows, the increase in Mdm2 levels was
dependent on the kinase activity of Src. It is noteworthy that the
observed increases in Mdm2 protein levels are not dependent on
p53 (H1299 cells are devoid of p53) or Src signaling-mediated
mdm2 gene expression (Fig. S2 A and B).
To determine whether growth factors could alter Mdm2 levels
through the activation of c-Src, epidermal growth factor (EGF)
was incubated with MCF7 cells that were serum-starved for 48 h.
Mdm2 levels increased with EGF stimulation until a plateau was
achieved at 30 min (Fig. 3C). Pretreatment with c-Src inhibitors
PP1 (Fig. 3D) or saracatanib (Fig. 3E) prevented the increase in
Mdm2. Thus, the increase in endogenous Mdm2 protein is a re-
sult of activated c-Src.
Src Phosphorylation Alters the Enzymatic Activity and Half-Life of
Mdm2. We next examined whether the increased Mdm2 levels
in response to Src activation were a result of an increase in half-
life by treating transfected H1299 cells with cycloheximide. In
the presence or absence of kinase dead Src (KD)-Src, the half-
life of Mdm2 was 25 min (Fig. 4A, Left). In the presence of
CA-Src, the half-life of Mdm2 more than doubled, increasing to
Fig. 1. Mdm2 and c-Src form a complex in vitro and in vivo. (A) Schematic of
Mdm2 is shown (Top). His-tagged Mdm2 and GST-tagged SH3Src from a nickel
pull-down of His-Mdm2, His-Mdm2 SH3 domain mutant 1, and His-Mdm2 SH3
domain mutant 2 were immunoblotted for GST and His antibodies. Input is GST-
SH3Src. (B) Immunoprecipitations of endogenous Mdm2 from 293T (Left) or c-Src
from MCF7 and U87 cell extracts (Center and Right) were probed with Src and
Mdm2 antibodies. (C) Mdm2 and c-Src were detected by immunoblot of cyto-
plasmic and nuclear extracts from MCF7 cells. Detection of tubulin and PARP
indicate extract purity.
Fig. 2. c-Src phosphorylates Mdm2 at tyrosines 281 and 302. (A) The total
and the defined tyrosine phosphorylation sites (P) in Mdm2 are illustrated.
(B) An in vitro phosphorylation reaction of Mdm2 (p-Mdm2) by c-Src or c-Abl
using 32P was detected by autoradiography. Autophosphorylation of c-Src
and c-Abl, along with c-Abl phosphorylation of Mdm2, served as internal
controls. (C) Immunoblot of in vitro phosphorylation reactions with Src and
Mdm2 was probed with the 4G10 antibody to detect phospho-tyrosines
(pTyr) (Right). (Left) Immunoblot of the input probed with SMP14. (D) HA-
Mdm2 was immunopurified from H1299 cells that have been transiently
transfected with HA-Mdm2 and KD-Src or CA-Src. Immunoblots were probed
with anti-HA antibodies or the p-Tyr antibody, 4G10, to show tyrosine phos-
phorylation of Mdm2. Immunoblot (Bottom) was probed with Src to show
expression in lysates. (E) Mdm2 was immunoprecipitated from MCF7 extracts
after treatment with 10 μM PP1 or DMSO for 16 h and immunoblotted for
p-Tyr and Mdm2. (F) In vitro phosphorylation reactions were performed with
Src on His-tagged 90–383 Mdm2 and the Y281-302F double mutant.
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70 min (Fig. 4A, Left). The half-life of the mutant Mdm2 remained
at 25 min, the same as wild-type Mdm2 without Src or in the
presence of KD-Src (Fig. 4A, Right). Therefore, Src-dependent
phosphorylation of Mdm2 increased the half-life of Mdm2, sug-
gesting the ubiquitin ligase activity of Mdm2 is not operative.
When the autoregulatory loop is engaged, Mdm2 is associated
with decreased p53 levels; this decrease is a result of the Mdm2-
dependent ubiquitination of p53. In fact, ectopic expression that
leads to high levels of Mdm2 has been reported to facilitate poly-
ubiquitination of p53 (19). Because c-Src phosphorylation results
in increased Mdm2 levels, we examined whether ubiquitination
of p53 would be evident. An in vitro ubiquitination assay of p53
was performed using unphosphorylated, Src, or Abl-phosphory-
lated Mdm2. c-Abl is known to inhibit Mdm2 ubiquitination of
p53, and thus served as a control (6, 7). As shown in Fig. 4B,
phosphorylation with c-Src inhibited the ubiquitination of p53 to
the same extent as c-Abl. Furthermore, we examined whether
the loading of ubiquitin to Mdm2 was altered by phosphorylation
in transient transfection assays. In the presence of CA-Src, ubiq-
uitinated Mdm2 was dramatically diminished compared with
Mdm2 alone (Fig. 4C, Left). These data are consistent with the
in vitro assays in Fig. 4B. Because tyrosine phosphorylation of
Mdm2 was implicated with loss of activity (Fig. 4B), we also de-
termined whether the neddylating activity associated with Mdm2
was also decreased with Src phosphorylation. To our surprise,
Mdm2 was neddylated in the presence of c-Src (Fig. 4C, Right).
Because Mdm2 activity is specified by which E2 it binds, we
determined whether Src phosphorylation of Mdm2 increased the
association with Ubc12 (the E2 ligase for Nedd8). Immunoblot
analysis of a GST pull-down assay shows that unphosphorylated
Mdm2 bound to Ubc5a (the E2 ligase for ubiquitin) preferen-
tially over Ubc12, which was diminished with Src-phosphorylated
Mdm2. Conversely, an increase in the Ubc12/Mdm2 interaction
was observed with Src-phosphorylated Mdm2 (Fig. 4D). This
experiment provides evidence that Src phosphorylation of Mdm2
changes the recruitment of E2 enzymes. Indeed, endogenous
Ubc12 copurified endogenous Mdm2 (Fig. 4E) and endogenous
Mdm2 copurified endogenous Ubc12 (Fig. S2C). We also ex-
amined whether transiently expressed HA-Mdm2 or HA-Mdm2
(Y281-302F) would purify Ubc12. Dominant negative Ubc12
was used to eliminate the potential for a transient interaction
between Mdm2 and an active Ubc12. The data in Fig. 4F show
that immunoprecipitation of Mdm2 purified Ubc12, but not
the Y281-302F mutant of Mdm2. These data support a novel
Fig. 3. c-Src phosphorylation results in an enhancement of Mdm2 protein
levels. (A) Immunoblot analysis was performed with H1229 cells over-
expressing Mdm2 that had been treated with increasing concentrations (0.5,
1, 5, 10 μg) of CA-Src. (B) Cellular extracts of H1299 cells ectopically
expressing Mdm2 alone or with CA-Src or KD-Src were immunoblotted for
Mdm2, c-Src, and GAPDH. (C) MCF7 cells were serum starved for 48 h and
then treated with 200 ng/mL EGF for the time indicated. Endogenous Mdm2,
p-Src, and GAPDH (for loading) were analyzed by immunoblot. The asterisk
indicates a nonspecific band. (D) MCF7 cells were serum starved for 48 h and
then pretreated with either DMSO or PP1 (10 μM) for 1 h before the addition
of EGF (200 ng/mL). EGF treatment of 1 h was followed by immunoblot
analysis of Mdm2 and GAPDH. The asterisk indicates a nonspecific band. (E)
Mdm2 levels (and GAPDH as control) in MCF7 cells pretreated with sar-
acatanib or DMSO overnight followed by EGF for 1 h were detected by
immunoblotting. The asterisk indicates a nonspecific band.
Fig. 4. c-Src expression increases the half-life of Mdm2 through inhibition
of its E3 ubiquitination activity. (A) H1299 cells were transfected with Mdm2
(Left) or Y281-302F Mdm2 (Right) and CA-Src, KD-Src, or empty vector (pUSE)
in the presence of Myc-LacZ vector. Twenty-four hours posttransfection, the
cells were treated with 50 μg/mL cycloheximide (CHX) and harvested at
different points, as indicated. The cell lysates were immunoblotted with
anti-Mdm2 and anti-Myc antibodies, as indicated (Top). The density of
Mdm2 in each lane was quantified against the level of Myc-LacZ and plotted
in a graph (Bottom). The asterisk indicates a nonspecific band. (B) An in vitro
ubiquitination assay was performed with recombinant p53, using Mdm2 or
Mdm2 phosphorylated by c-Src/c-Abl. Immunoblot was probed for p53 (D01).
(C) A His pull-down assay was used to determine whether Mdm2 was either
His-ubiquitinated (Left) or His-neddylated (Right) in the presence of CA-Src.
Immunoblots were used to detect Mdm2. (D) A GST-pull-down of GST, GST-
Ubc5, or GST-Ubc12 was used to determine whether Mdm2 or c-Src-phos-
phorylated Mdm2 would preferentially complex to an E2. Mdm2 and GST
were detected by immunoblot. (E) Cellular extracts from MCF7 cells were
used to immunoprecipitate Ubc12 or isotype control. Mdm2 and Ubc12 were
detected by immunoblot. (F) Immunoblots detected Ubc12 and HA, from
immunoprecipitations of HA from 239T cells transiently transfected with
combinations of HA-Mdm2, HA-Y281-302F Mdm2, and DN-Ubc12.
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mechanism by which Src-mediated tyrosine phosphorylation of
Mdm2 increases binding to Ubc12 and the formation of a
neddylating complex.
Regulation of p53 by c-Src-Phosphorylated Mdm2. Because we
have established that Src-phosphorylated Mdm2 complexes
with Ubc12, we examined whether p53 would be a substrate.
Initially, we incubated MCF7 cells with EGF and examined
endogenous p53 levels over a time course. Immunoblot analysis
shows that p53 increased (Fig. 5A), which is consistent with
c-Src activation, increased Mdm2 protein levels (Fig. 3C),
and decreased ubiquitination (Fig. 4B). To examine whether
blockade of c-Src would affect p53 levels, actively growing MCF7
cells were treated with PP1. We observed decreasing levels of
p53 as PP1 concentrations increased (Fig. 5B). This supports
a switch in Mdm2 from a Src-dependent neddylating enzyme to
a ubiquitinating enzyme. In addition, transfection of Mdm2
alone and with KD-Src resulted in decreased p53, whereas p53
levels were elevated in the presence of Mdm2 and CA-Src (Fig.
5C). To confirm that p53 stabilization in response to active Src
requires Mdm2, we transiently transfected p53 into p53−/− or
p53−/−Mdm2−/− murine embryo fibroblasts (MEFs), and treated
with PP1 (Fig. 5D). In the absence of Mdm2 (p53−/−Mdm2−/−),
p53 levels remained unchanged with PP1 treatment. Conversely,
in the presence of Mdm2 (p53−/−), PP1 treatment resulted in
a decrease in ectopically expressed p53. Collectively, these results
show that c-Src phosphorylation of Mdm2 results in the stabili-
zation of p53 levels. Furthermore, Fig. 5E shows that in the
presence of PP1 treatment, fewer Nedd8 conjugated proteins
copurified with p53 compared with actively growing cells. Al-
though these data show that a p53 complex is neddylated in re-
sponse to c-Src activation, this does not provide direct evidence
that p53 was neddylated. To address this issue, we transfected
H1299 cells with a His-Nedd8 construct, along with p53, Mdm2,
and CA-Src or KD-Src, and conducted a nickel pull-down assay
to isolate His- tagged, neddylated proteins. Fig. 5F illustrates that
in the presence of CA-Src, neddylated p53 dramatically increases.
As expected, Nedd8 conjugated to p53 was absent when KD-Src
was present (Fig. 5F), which indicates that the neddylating activity
of Mdm2 is dependent on active Src. To provide further evidence
that the switch of Mdm2 to neddylating activity was dependent on
Src-phosphorylation, a His-Nedd8 pull-down assay using the
Mdm2 phosphorylation-deficient mutant Y281-302F was per-
formed. The neddylation of p53 increases dramatically in the
presence of WT Mdm2 and CA-Src, but not in the presence of
Y281-302F and CA-Src (Fig. 5G). Furthermore, we found that
the Y281-302 mutant of Mdm2 generated more ubiquitinated p53
than wild-type Mdm2 (Fig. S2D). Considering that Mdm2 is
functioning as part of a neddylating complex under growth
conditions, we sought to determine whether this activity could
be disrupted pharmacologically. Recently, a potent inhibitor,
MLN4924, that targets the Nedd8-activating enzyme was de-
veloped (20). This compound blocked the Mdm2-mediated p53
neddylation (Fig. 5H). Taken together, increased p53 levels result
from c-Src activation of the neddylating function of Mdm2.
p53 Levels Are Divorced from Transcriptional Activity. We have
established that Src-phosphorylation leads to increased neddylated-
p53, and considering that increased levels of p53 are not necessarily
an indication of transcriptional activity, we tested whether p53 was
transcriptionally active under conditions of neddylation. We initi-
ated our study using PG13-Luc, which is an artificial p53 responsive
promoter linked upstream of luciferase, along with combinations of
p53, Mdm2, CA-Src, and beta-galactosidase (internal control for
transfection efficiency) and/or treatment with MLN4924. As pre-
dicted, in the presence of Mdm2, p53 activity was diminished, and
a further decrease was evident when CA-Src was present. This
decrease in p53 activity was reversed to a level similar to that in
Mdm2 alone with MLN4924 treatment (Fig. 6A).
We next determined whether the Src-Mdm2-Nedd8-p53 axis
regulates the tumor suppressor Maspin, which plays an impor-
tant role in regulating tumor cell invasion and metastasis (21).
We have previously shown that p53 is required for the up-reg-
ulation of maspin under hypoxic conditions in glioblastoma cell
lines (22). The data in Fig. 6B show that p53 drives the expres-
sion of luciferase from the maspin promoter and that a decrease
is seen with Mdm2 overexpression. Just like with the PG13-Luc,
expression of CA-Src further inhibits p53 activity on the maspin
promoter, and this inhibition is dependent on neddylation. The
Fig. 5. p53 protein levels are regulated by c-Src-phosphorylated Mdm2. (A)
MCF7 cells were serum starved for 48 h and incubated with EGF over a time
course of 1 h. Extracts were immunoblotted for p53 and GAPDH. (B) MCF7 cells
were treated with increasing concentrations of PP1 (1, 5, 10, 15, 20 μM) for
16 h. Cellular extracts were immunoblotted for p53 and GAPDH. (C) Lysates
from H1299 cells overexpressing combinations of p53, Mdm2, CA-Src, or KD-Src
were immunoblotted for Mdm2, p53, Src, and GAPDH. (D) Cellular extracts
from p53−/− or p53−/− Mdm2−/− MEFs that had been transiently transfected
with p53 and treated with PP1 (10 μM) or DMSO were immunoblotted for p53
and GAPDH. (E) Immunoprecipitations of p53 and IgG control from MCF7
cellular extracts were used to detect endogenous Nedd8 and p53 in immu-
noblots. Cells were either treated with PP1 (10 μM) or DMSO for 16 h. (F) p53
was detected by immunoblot from a His-Nedd8 pull-down assay conducted in
H1299 cells expressing His-Nedd8, p53, WT-Mdm2, CA-Src, or KD-Src. To verify
expression, lysates were subjected to immunoblot analysis, as indicated. (G)
His-Nedd8 pull-down was performed as in F, but with the use of Mdm2-Y281-
302F, as indicated. (H) H1299 cells were transfected with p53, Mdm2, and CA-
Src 24 h before treatment with either DMSO or 0.3 μMof the Nedd8-activating
enzyme inhibitor MLN4924 for 16 h. Immunoblot detected p53 and GAPDH
and relative amounts of p53 were determined.
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Src phosphorylation sites in Mdm2 were necessary for the
additional decrease in p53 activity, as maspin-luc activity was
equally inhibited with or without CA-Src when the Y281-302F
Mdm2 was present (Fig. 6C). This experiment shows that Mdm2,
when phosphorylated at Y281 and Y302, is more effective at
repressing p53-mediated maspin gene expression. When MCF7
cells were transfected with the maspin-luc construct or a mutant
maspin-luc (MT1) that is unresponsive to p53, activity from the
MT1 promoter was significantly lower than that from the maspin-
luc promoter, demonstrating that luciferase activity was de-
pendent on endogenous p53 (Fig. 6D). Treatment of cells with
PP1 resulted in an increase in endogenous p53 activity (Fig. 6D).
We next examined whether the activity observed in the transient
reporter assays was reflected in endogenous Maspin protein lev-
els. Similar to the reporter assays, when the neddylating activity of
Mdm2 was impeded by treatment with PP1 or MLN4924, Maspin
protein levels increased as a result of the alleviated repression of
p53 activity (Fig. 6E). Together, these findings show that ned-
dylation of p53 is responsible for a reduction in p53 activity.
Discussion
Mdm2 is interesting clinically, as the gene is amplified in 10% of
all human cancers, yet the protein is detectable in 40–90% of cases
(23). This increase in detectable Mdm2 in cancer raises questions
as to how Mdm2 is elevated. Mdm2 is undetectable in normal
tissue, and external stimuli might be involved in elevating levels in
cancer. Indeed, the current paradigm is that the mdm2 gene is
a transcriptional target of the p53 tumor suppressor, in response to
stress signals such as low genotoxic stress. This pathway then forms
an autoregulatory feedback loop to down-regulate p53 through the
proteasome. However, there may be other mechanisms that can
elevate Mdm2. Because the tumor microenvironment has high
concentrations of numerous growth factors and cytokines, these
factors may play a role in regulating Mdm2. In fact, recent work
shows that sustained TGFβ1 exposure induces the Smad3/Smad4
complex to bind the promoter of mdm2 and increase gene ex-
pression, an event independent of p53 activity (24).
Several growth factors including EGF can activate c-Src (25),
and considering that c-Src is downstream of many growth factors,
it is not surprising that c-Src functions poorly as an oncogenic
factor on its own. c-Src is integrated into a number of normal and
pathologic processes, including proliferation, survival, motility,
and angiogenesis (1, 26). In support of Src mediating oncogenic
signaling, we show that the oncogene Mdm2 interacts with, and
is a downstream target of, c-Src (Figs. 1 A–C and 2 B–F). The
phosphorylation of Mdm2 by c-Src occurs on tyrosines 281 and
302 (Figs. 2F and S1B), which are within or close proximity to the
zinc finger domain of Mdm2. Recent work has shown that the
zinc finger domain is important for the half-life of Mdm2, which
is supported by a C305F mutation that results in loss of ubiquitin
ligase activity (27). Through the use of ectopically expressed
constitutively active Src or activation by EGF, we show that Src
phosphorylation of Mdm2 results in an increase in Mdm2 protein
stability (Figs. 3 and 4). Therefore, our study and published work
on the zinc finger support the notion that this domain of Mdm2 is
highly regulated and is pivotal in controlling Mdm2 activity.
There is a complex interplay between p53 and Mdm2, where
Mdm2 may block p53 transcriptional activity without de-
stabilization by masking p53’s N-terminal transactivation domain
(28). This phenomenon is evident as C464S, the RING finger
mutant of Mdm2, is embryonically lethal, akin to the mdm2−/−
mouse, despite still being efficient at inhibiting p53 transcrip-
tional activity (29). This finding provides evidence that the ligase
activity of Mdm2 is necessary to regulate p53 during specific
windows of development. In parallel with these studies, our data
illustrate that the C464S mutant can inhibit p53, yet the RING
domain of Mdm2 is required for a robust reduction in p53 ac-
tivity in the presence of CA-Src (Fig. S3A).
Although much is known about the role of Mdm2 during
genotoxic stress, very little information has been generated on
how Mdm2 is functioning under conditions of growth. We show
that signaling pathways emanating from cell surface receptors
result in c-Src phosphorylation at Y281 and Y302, which “flips
the switch” for Mdm2 to become a neddylating enzyme (Figs. 4C
and 5 E–H). Phosphorylation at these sites is required for re-
cruitment of Ubc12, the conjugation of Nedd8 to p53, and thus,
inactivation of p53 (Figs. 5 and 6). Initial work showing that
Mdm2 has neddylating activity on p53 did not provide a mecha-
nism of how this activity was engaged (11).
Fig. 6. Increased p53 levels do not translate to increased transcriptional
activity. (A) PG13-Luc activity was assayed using H1299 cells transfected with
Myc-LacZ, p53, Mdm2, and CA-Src. Twenty-four hours posttransfection, cells
were treated with DMSO or 0.3 μM of the Nedd8-activating enzyme in-
hibitor MLN4924 for 16 h. (B) H1299 cells were treated the same as in A,
except luciferase was assayed using Maspin-Luc and Myc-LacZ. (C) maspin-
luciferase activity was examined in H1299 cells transfected with p53, Mdm2
Y281-302F, and CA-Src. (D) Luciferase assay of MCF7 cells transfected with
either Maspin-Luc or Mutant Maspin-Luc (MT) and Myc-LacZ was conducted.
Twenty-four hours after transfection, cells were treated with DMSO or
10 μM PP1 for 16 h. (A–D) Y axis measurements are relative luciferase units
(RLU). The RLU were calculated from the ratio of luciferase/β-gal activity.
Error bars represent SD of three separate experiments. *,#P < 0.05. (E) MCF7
cells were treated with DMSO or 10 μM PP1 and subjected to immunoblot-
ting for Maspin and GAPDH. (F) In response to activated Src, Mdm2 is
phosphorylated and selectively binds to Ubc12 to function as a neddylating
enzyme. The respective inhibitors to the pathway are denoted.
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The conjugation of nedd8 to p53 could be reversed in response
to genotoxic stress, as the deneddylating enzyme NEDP1 is
activated (30) and can then reverse neddylation of p53. This
finding shows that there are distinct pathways that regulate p53,
which are dependent on specific stimuli. It could be envisioned
that if growth signals are dominant, then the genotoxic signaling
would be tempered, and p53 activity minimalized. Thus, un-
derstanding how signaling pathways promote growth and cell
death will be key for the development of therapeutic approaches
to activate a robust p53 response.
Inhibition of global neddylation with MLN4924 leads to apo-
ptotic death in human cancer cells and suppresses the growth of
human tumors in mouse xenografts (23). In fact, we observed that
loss of Src/Nedd8 activity leads to decreased cell survival (Fig. S3B).
This result corresponded with inhibition of the neddylation activity
of Mdm2 with PP1 and MLN4924 (Fig. 6), unneddylated p53, and
the induction of the downstream targetmaspin gene. p53 can target
many genes including maspin, which can be induced in the absence
of extrinsic genotoxic stress (22). Maspin is normally highly ex-
pressed in normal breast epithelial cells, but is down-regulated in
invasive and metastatic breast carcinoma cells (31). Clinically, its
expression correlated with decreased microvessel staining in hu-
man breast cancer samples (32), and our work shows induction
when we inhibit the neddylation activity of Mdm2 with PP1 and
MLN4924 (Fig. 6). Thus, we have identified Src, Mdm2, Ubc12,
and NEDD8 as components of a pathway that impedes the ability
of p53 to induce maspin (Fig. 6F). This pathway can be reversed
pharmacologically to increase protein levels, which may negatively
affect tumor progression in cancers that maintain p53 genetically.
Methods
Cell Culture and Treatments. Cells were cultured are described in SI Methods.
Protein Analysis and Immunoprecipitation. Whole-cell extracts (lysates) were
prepared as described and used for Western blot analysis or immunopre-
cipitation (6). Additional information regarding reagents and buffers and in
vitro reactions is located in SI Methods.
Statistical Analysis. All statistical analysis was done using a two-tailed t test
with unequal variance.
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